• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Gilead Sciences (NQ: GILD )

    88.29 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Gilead Sciences

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    51 52 Next >
    Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
    The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
    Via Benzinga
    3 Stocks at 52-Week Lows Poised for a Powerful Rebound
    Starbucks, Gilead, and Vale are three stocks at 52-week lows that show signs of recovery potential and long-term growth prospects. 
    Via InvestorPlace
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
    From Gilead Sciences, Inc.
    Via Business Wire
    If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,000 Today
    Via Benzinga
    Analyzing NASDAQ:GILD's Dividend Potential.
    Is GILEAD SCIENCES INC (NASDAQ:GILD) a Good Fit for Dividend Investing? 
    Via Chartmill
    If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,100 Today
    Via Benzinga
    Starbucks, Gilead And Ambev Are At 52-Week Lows: Should You Buy The Dip?
    Capital market investors often look for entry points, hidden gems, and value bets. Quality stocks trading at or around their 52-week low levels offer one such opportunity window. 
    Via Benzinga
    3 No-Brainer Dividend Stocks to Buy in April
    Income investors will find a lot to like about these stocks. 
    Via The Motley Fool
    Got $5,000? These 3 High-Yielding Dividend Stocks Are Trading Near Their 52-Week Lows
    All of these stocks pay generous dividends that income investors will appreciate. 
    Via The Motley Fool
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Biotech Sector Nears Breakout: Will it Outperform in Q2?
    The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains 
    Via MarketBeat
    Topics ETFs
    5 Healthcare Stocks to Buy for 2024
    Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up. 
    Via InvestorPlace
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst
    BofA Securities downgrades Galapagos to underperform due to limited near-term catalysts and competitive challenges in crowded markets. 
    Via Benzinga
    10 Big-Name Stocks Near 52 Week Lows: Are They A Buy?
    Over the past twelve months, a number of big-name companies have been near or below their 52-week low price. Each week we’ll take a look at some of the biggest names currently close to their 52-week... 
    Via Talk Markets
    Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session - Here's Why
    Xilio Therapeutics soars with exclusive license pact with Gilead Sciences to advance XTX301, a Phase 1 tumor-activated IL-12 program. $43.5 million upfront, $604 million potential payments, and tiered... 
    Via Benzinga
    Why Is Xilio Therapeutics (XLO) Stock up 168% Today?
    Xilio Therapeutics stock is heading higher on Thursday with heavy trading of XLO shares after announcing a deal with Gilead. 
    Via InvestorPlace
    FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
    From Gilead Sciences, Inc.
    Via Business Wire
    Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
    From Gilead Sciences, Inc.
    Via Business Wire
    Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
    From Xilio Therapeutics, Inc.; Gilead Sciences, Inc.
    Via GlobeNewswire
    7 Value Stocks to Buy at a 52-Week Low in March
    These seven value stocks to buy all trade at low valuations, and have the potential to make big recoveries. 
    Via InvestorPlace
    Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
    During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
    Via Benzinga
    Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
    Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom. 
    Via InvestorPlace
    2 Top Dividend Stocks to Buy Hand Over Fist
    Every company faces headwinds eventually. The top ones know how to bounce back. 
    Via The Motley Fool
    10 Big-Name Stocks Near 52-Week Lows: Are They A Buy?
    Over the past twelve months a number of big named companies have been near or below their 52 week low price. Each week we’ll take a look at some of the biggest names currently close to their 52 week... 
    Via Talk Markets
    Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production
    Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology. Anticipating a... 
    Via Benzinga
    Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
    From Gilead Sciences, Inc.
    Via Business Wire
    3 Dividend Stocks to Buy Hand Over Fist in March
    Income investors might want to load up on these great dividend stocks. 
    Via The Motley Fool
    The AI Race Gets Litigious
    We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade. 
    Via The Motley Fool
    Topics Artificial Intelligence Intellectual Property
    Exposures Artificial Intelligence Intellectual Property
    FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
    FDA grants accelerated approval to BeiGene's Brukinsa for relapsed/refractory follicular lymphoma. Approved in combination with Roche's Gazyva after two or more lines of therapy. Brukinsa, priced at... 
    Via Benzinga
    Exposures Product Safety
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    51 52 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.